Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook
Medpace Holdings Inc. (NASDAQ: MEDP ) stock is trading higher on Thursday on better-than-expected second-quarter financial results and raised its fiscal 2026 guidance. The clinical contract research organization reported earnings of $4.25, beating the consensus of $3.97. The company reported sales of $707.33 million, surpassing the consensus of $687.65 million. Revenues increased 17.2% year over year, representing a backlog conversion rate of 24.1%. EBITDA climbed 17.6% to $153.4 million, representing 21.7% of total revenue. Backlog Continues To Grow Meanwhile, the company’s project backlog grew 4.9% year-over-year to over $3.01 billion. Net new business awards hit $795.7 million for the quarter, generating a healthy net book-to-bill ratio of 1.13x. CEO August Troendle in the earnings conference call said, “Cancellations were well-behaved and supported a record quarter for net b...
Medpace Holdings Inc. (NASDAQ: MEDP ) stock is trading higher on Thursday on better-than-expected second-quarter financial results and raised its fiscal 2026 guidance. 97. 65 million.
1%. 7% of total revenue. 01 billion. 13x.
CEO August Troendle in the earnings conference call said, “Cancellations were well-behaved and supported a record quarter for net bookings. ” “Overall, the environment remains constructive into July, and we are making good progress in positioning the business for 2027,” Troendle further commented. 97. 778 billion.
0 million. 31 at the time of publication on Thursday, according to Pro data. Read Also: Jim Cramer: ‘Regional Banks Have Been A Fantastic Place To Be’ Photo: Shutterstock